Dose-Dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials

Journal of the National Cancer Institute

Volumn 102, Issue 24, 2010, Pages 1845-1854

  Bonilla, Luisa ^a   Ben Aharon, Irit ^a,b   Vidal, Liat ^a,b   Gafter Gvili, Anat ^a,b   Leibovici, Leonard ^a,b   Stemmer, Salomon M ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COCHRANE LIBRARY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HAZARD RATIO; HUMAN; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MODELS, STATISTICAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650384680     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq409     Document Type: Article

References (30)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005; 365(9472):1687-1717.
2. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987;14(1):65.
3. Biganzoli L, Piccart MJ. The bigger the better? Or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol. 1997;8(12):1177-1182.
4. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and effcacy. J Clin Oncol. 1999;17(1):93-100.
5. Norton La: A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24, pt 1):7067.
6. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: frst report of intergroup trial C9741. Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8): 1431-1439.
7. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97(23):1724-1733. (Pubitemid 41782282)
8. Baldini E, Gardin G, Giannessi PG, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fuorouracil or cyclophosphamide, methotrexate and 5-fuorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol. 2003;14(2):227-232.
9. Untch M, Thomssen C, Steffen K, et al. Five year results of a randomized multicenter dose intense (DI-EC) study with epirubicin (E) and cyclo-phosphamide (C) in high risk breast cancer patients: a treatment of short duration with comparable effcacy to conventional chemotherapy. Breast Cancer Res Treat. 2002;76(suppl 1):S158. Abstract 641.
10. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16(10):3353-3361.
11. Linden HM, Haskell CM, Green SJ, et al. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: fnal analysis from INT-0137 (S9313). J Clin Oncol. 2007;25(6):656-661.
12. Möbus VJ, Untch M, Du Bois A, et al. Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial. Proc Am Soc Clin Oncol. 2004;22(suppl July 15):S14. Abstract 513.
13. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fuorouracil with dose intensifed epirubicin and cyclophosphamide plus flgrastim as neoadjuvant treatment in locally advanced breast cancer. An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21(5): 843-850.
14. Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophos-phamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23(12):2676-2685.
15. Kümmel S, Krocker J, Kohls A, et al. Randomised trial: survival beneft and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer. 2006;94(9):1237-1244.
16. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27(18):2938-2945.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
18. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315(7109):629-634.
19. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0. The Cochrane Collaboration; 2008. www.cochrane-handbook.org. Accessed September 30, 2008.
20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-748.
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
23. Burnell M, Levine M, Chapman JA, et al. Cyclophosphamide, epirubicin, and fuorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010;28(1):77-82.
24. Untch M, Fasching PA, Bauerfeind I, et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensifed chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/ cyclophosphamide followed by paclitaxel ± darbapoetin alfa in primary breast cancer: a preplanned interim analysis of effcacy at surgery. J Clin Oncol. 2008;26(suppl May 20). Abstract 517.
25. Kümmel S, Rezai M, Kimmig R, Schmid P. Dose-dense chemotherapy for primary breast cancer. Curr Opin Obstet Gynecol. 2007;19(1):75-81. (Pubitemid 46095877)
26. Doorduijn JK, Buijt I, Van Der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica. 2004;89(9):1109-1117.
27. Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19): 2991-2997.
28. Yerushalmi R, Kramer MR, Rizel S, et al. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol. 2009;20(3):437-440.
29. Ellis GK, Green SJ, Russell CA, et al. SWOG 0012, A randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophos-phamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for infammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(12s) (suppl 18); LBA537. 30.
30. McArthur HL, Hudis CA. Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data. Clin Breast Cancer. 2007;(suppl 1): S6-S10.